Aclaris Therapeutics, Inc.
ACRS
$1.52
$0.0251.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -39.32% | -47.58% | -53.18% | 47.99% | -5.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -39.32% | -47.58% | -53.18% | 47.99% | -5.14% |
| Cost of Revenue | 12.11% | -40.60% | -73.92% | -60.29% | -52.22% |
| Gross Profit | -25.39% | 31.38% | 82.37% | 68.39% | 57.65% |
| SG&A Expenses | -10.30% | -32.27% | -20.28% | -42.86% | -22.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.83% | -39.01% | -64.20% | -56.17% | -44.27% |
| Operating Income | -10.25% | 31.70% | 67.63% | 62.02% | 47.49% |
| Income Before Tax | 10.96% | -5,096.56% | 74.07% | 62.85% | 39.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.96% | -6,375.65% | 74.07% | 62.85% | 39.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 10.96% | -6,375.65% | 74.07% | 62.85% | 39.84% |
| EBIT | -10.25% | 31.70% | 67.63% | 62.02% | 47.49% |
| EBITDA | -11.06% | 31.48% | 67.77% | 62.01% | 47.61% |
| EPS Basic | 48.28% | -4,724.29% | 74.27% | 63.19% | 43.39% |
| Normalized Basic EPS | 39.26% | 55.79% | 75.59% | 65.59% | 54.08% |
| EPS Diluted | 48.28% | -4,216.17% | 74.27% | 63.19% | 43.39% |
| Normalized Diluted EPS | 39.26% | 55.79% | 75.59% | 65.59% | 54.08% |
| Average Basic Shares Outstanding | 72.20% | 34.49% | 0.81% | 0.93% | 6.28% |
| Average Diluted Shares Outstanding | 72.20% | 34.49% | 0.81% | 0.93% | 6.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |